HOW WE CAN HELP
Our patent lawyers aim to constantly challenge themselves and the 'accepted' approach to patent litigation. Each project is different and deserves its own strategy.
We approach patent litigation with a clear strategy, goal setting and action plans and by taking strong interlocutory and procedural action to deliver results. We use novel ways to get the best for our clients as opposed to the accepted usual ways of litigating. We work with Australia’s leading patent counsel and regularly work as part of multi-national teams on cross-border patent litigation. The majority of our team have technical and scientific qualifications.
Patent litigation demands excellent project management skills. Our patent law experts are adept at managing complex, multi-faceted patent cases and balancing the demands of multiple stakeholders. Our experience enables us to save considerable time and resources in identifying and addressing the core issues in a complex matrix.
On their successful special leave application to the High Court of Australia about the issue of exhaustion of patent rights for the first time in 112 years.
On strategic patent management and enforcement, including in Aristocrat Technologies v Konami Japan – Australia's longest-running and highest-value patent damages case.
On patent infringement and validity proceedings regarding our clients’ online search technology brought against SAI Global’s main competitor.
On its long-standing, multi-jurisdictional patent litigation against SNF Australia. The patents in issue related to chemical technologies in the mining and resources space.
On successfully conducting a patent enforcement program in respect of its mineral exploration technologies.
On patent infringement proceedings about its use of Ariosa, Inc.’s 'Harmony' prenatal test by Sequenom, Inc., which offers the competing 'MaterniT21' genetic test.
On multi-jurisdictional high-stakes patent infringement litigation against key competitor, Fisher and Paykel.
On the commercialisation of its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer.
In relation to IP and TGA regulatory issues in its acquisition of Laser Clinics Australia's non-invasive aesthetic treatments business for $650 million.
